Skip to main content
. 2023 Mar 2;29(3):738–747. doi: 10.1038/s41591-023-02225-7

Fig. 2. Performance diagrams of the MPXV-CNN for the validation and testing cohorts.

Fig. 2

a, ROC curve derived from repeated fivefold cross-validation on the validation cohort (AUC = 0.967 ± 0.003). b, Confusion matrix on the testing cohort showing the ratios of TPs (0.91), TNs (0.898), FPs (0.102) and FNs (0.09). c, ROC curve of the testing cohort that included MPXV skin lesions and either acute non-MPXV skin lesions (AUC = 0.962), chronic non-MPXV skin lesions (AUC = 0.967) or all non-MPXV skin lesions (AUC = 0.966). FPs, false positives; FNs, false negatives; ROC, receiver operating characteristic; TPs, true positives; TNs, true negatives.